Symbols

KRMD

KORU Medical·NASDAQ

--(--)

KRMD fundamentals

KRMD Q4 2025 Earnings

KORU Medical (KRMD) released its earnings on Mar 12, 2026: revenue was 10.90M (YoY +23.27%), beat estimates; EPS was -0.01 (YoY +66.67%), beat estimates.

Revenue / YoY

10.90M

+23.27%

EPS / YoY

-0.01

+66.67%

Report date

Mar 12, 2026

KRMD Earnings Call Summary for Q4,2025

CEO Transition: Linda Tharby retiring; Adam Kalbermatten to lead, ensuring strategic continuity.
Revenue Growth: 2025 full-year $41.1M (+22% YoY); 2026 guidance $47.5M-$50M (+15%-22%).
Strategic Milestones: EU MDR certification, RYSTIGGO clearance, 80% international growth.
Financial Health: Positive cash flow, 62.3% gross margin, 2026 EBITDA positivity.
Future Opportunities: Oncology pipeline, Japan expansion, 3M+ annual infusions from new therapies.

Earnings

EPS

Revenue

Revenue & Expenses

KRMD has released its 2025 Q4 earnings report, with revenue of 10.90M, reflecting a YoY change of 23.27%, and net profit of -486.86K, showing a YoY change of 68.81%. The Sankey diagram below clearly presents KRMD's revenue sources and cost distribution.

Key Indicators

KORU Medical (KRMD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

KORU Medical (KRMD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

KORU Medical (KRMD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

KORU Medical (KRMD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown